| P2093 | author name string | Haruhiko Nakamura | |
| | Norihito Kawasaki | |
| | Masahiko Taguchi | |
| | Kazuyuki Kabasawa | |
| P2860 | cites work | Bias in meta-analysis detected by a simple, graphical test | Q24685585 |
| | EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 |
| | Operating characteristics of a rank correlation test for publication bias | Q27860653 |
| | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 |
| | Meta-analysis in clinical trials | Q27860779 |
| | Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage | Q28272540 |
| | A biological staging model for operable non-small cell lung cancer | Q28367155 |
| | Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data | Q30655546 |
| | HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer | Q33201126 |
| | Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. | Q33359693 |
| | C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. | Q34124421 |
| | Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer | Q34483005 |
| | Beta blockade during and after myocardial infarction: an overview of the randomized trials | Q34557544 |
| | Gefitinib (Iressa) trials in non-small cell lung cancer | Q35179411 |
| | The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature | Q35216052 |
| | Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis | Q35587101 |
| | Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections | Q36135626 |
| | Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer | Q36623274 |
| | Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer | Q36642239 |
| | Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer | Q36695530 |
| | Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer | Q36799412 |
| | Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations | Q38318461 |
| | Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer | Q38475099 |
| | Prognostic value of the quantified expression of p185 in non-small cell lung cancer. | Q40762548 |
| | HER-2/neu oncogene protein and prognosis in breast cancer | Q41927421 |
| | Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung | Q43531194 |
| | Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer | Q44231768 |
| | Phosphorylation, But Not Overexpression, of Epidermal Growth Factor Receptor Is Associated With Poor Prognosis of Non-Small Cell Lung Cancer Patients | Q44399179 |
| | Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer | Q47252774 |
| | Effect of HER2/neu expression on survival in non-small-cell lung cancer | Q47289478 |
| | Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection | Q47782716 |
| | Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications | Q50876150 |
| | Language bias in randomised controlled trials published in English and German. | Q53358085 |
| | Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer | Q53494420 |
| | Study of prognostic predictors for non-small cell lung cancer. | Q53759964 |
| | Potential role ofbcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer | Q58212345 |
| | N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique | Q60035759 |
| | Publication Bias: A Problem in Interpreting Medical Data | Q63018176 |
| | Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma | Q72784859 |
| | Clinicopathologic analysis of k-ras, p53, and ERBB-2 gene alterations in pulmonary adenocarcinoma | Q73063449 |
| | p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma | Q73443407 |
| | Immunocytochemical markers in stage I lung cancer: relevance to prognosis | Q73585186 |
| | Molecular biologic substaging of stage I lung cancer according to gender and histology | Q73633029 |
| | Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung | Q74427809 |
| | Do molecular markers predict survival in non-small-cell lung cancer? | Q74489957 |
| | Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer | Q74498678 |
| | The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients | Q74522923 |
| | HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival | Q74599860 |
| | A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers | Q74652194 |
| | Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma | Q77357239 |
| | Publishing negative data: beta-tubulin mutations in lung cancer | Q77374037 |
| | Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer | Q77585746 |
| | Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study | Q77700543 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| | lung carcinoma | Q18556110 |
| | overexpression | Q61643320 |
| P304 | page(s) | 1865-1873 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis | |
| P478 | volume | 103 | |